SCHEMBL7959264

SCHEMBL7959264

Fc1ccc(C2CCN(CCCc3nnc4n3CCCCC4)CC2)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.53
SHMT2 P34897 1/20 0.53
GAA P10253 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.41
HPGD P15428 3/20 0.40
POLB P06746 2/20 0.40
HTR1A P08908 4/20 0.40
HTR2A P28223 4/20 0.40
DRD3 P35462 4/20 0.40
CHRM2 P08172 1/20 0.40
ADRA2A P08913 1/20 0.40
ADRA2B P18089 1/20 0.40
ADRA1D P25100 1/20 0.40
HTR2C P28335 1/20 0.40
SLC6A4 P31645 1/20 0.40
ADRA1A P35348 1/20 0.40
HTR2B P41595 1/20 0.40
PKM P14618 1/20 0.40
MCHR1 Q99705 1/20 0.39
DRD2 P14416 5/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7959555 0.92 LMNA (0.46) LMNASHMT2GAASMN1; SMN2HPGD
SCHEMBL7957361 0.88 DRD2 (0.48) LMNASHMT2GAASMN1; SMN2HPGD
Hydrochloric Acid SCHEMBL8570980 0.87 DRD2 (0.47) GAASMN1; SMN2HPGDPOLBHTR1A
SCHEMBL7964136 0.86 GAA (0.52) LMNASHMT2GAASMN1; SMN2HPGD
SCHEMBL7957315 0.86 LMNA (0.51) LMNAPOLBHTR1AHTR2ADRD3
SCHEMBL7963490 0.85 LMNA (0.46) LMNASHMT2GAASMN1; SMN2HPGD
SCHEMBL7959711 0.82 SLC6A4 (0.51) LMNAGAASMN1; SMN2HPGDPOLB
SCHEMBL7959702 0.82 TSHR (0.51) LMNAGAAHPGDPOLBHTR1A
SCHEMBL7957664 0.82 KDM4E (0.51) LMNAHPGDPOLBHTR1AHTR2A
SCHEMBL7961353 0.80 HTR1A (0.47) LMNASHMT2GAASMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6187774-B1 N-PIPERAZINYLALKYLINDAZOLE DERIVATIVES; PSYCHOLOGICAL DISORDERS, SCHIZOPHRENIA; SIDE EFFECT REDUCTION YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2001-02-13 US disclosed
EP-0885883-A1 FUSED HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1998-12-23 EP disclosed